Finance

Lists
CBIO:NASDAQ
Crescent Biopharma Inc
$15.83
-4.87%
(-0.81) 1D
$15.84
+0.06% (+0.010)
After hours
Closed: Jul 22, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
$16.66
High
$16.91
Low
$15.44
Mkt. cap
564.60M
Avg. vol.
414.25K
Volume
0.00
52-wk high
$27.41
52-wk low
$8.72
EPS
-$12.25
Beta
1.20
Shares outstanding
36.96M
No. of employees
55
Open
$16.66
High
$16.91
Low
$15.44
Mkt. cap
564.60M
Avg. vol.
414.25K
Volume
0.00
52-wk high
$27.41
52-wk low
$8.72
EPS
-$12.25
Beta
1.20
Shares outstanding
36.96M
No. of employees
55
News stories
From sources across the web
About Crescent Biopharma Inc
CEO-
Employees55
Founded2024
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitecrescentbiopharma.com
Analyst ratings
Based on 7 analysts giving stock ratings to CBIO in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current $15.83
$35.00 (+121.10%)
Average
$31.00 (+95.83%)
Lowest
$27.00 (+70.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
07/16/2026
Biren Amin
Piper Sandler
Buy
Maintained
$35.00
+121.1%
06/23/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$30.00
+89.5%
06/23/2026
Robert Driscoll
Wedbush
Buy
Maintained
$27.00
+70.6%
06/01/2026
Bradley Canino
Guggenheim
Buy
Maintained
$35.00
+121.1%
04/29/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$28.00
+76.9%
04/30/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
10.84M
1.04M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12.08M
20.35M
95.03M
17.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.95M
5.54M
7.31M
7.86M
Operating expense
21.03M
25.88M
102.34M
25.77M
Total operating expenses
21.03M
25.88M
102.34M
25.77M
Operating income
-21.03M
-25.88M
-91.49M
-24.73M
Other non operating income
-
-
-
-
EBT including unusual items
-21.79M
-24.61M
-90.40M
-23.28M
EBT excluding unusual items
-21.79M
-24.61M
-90.40M
-23.28M
Income tax expense
-
-
2.00M
-
Effective tax rate
-
-
-2.21%
-
Other operating expenses
-
-
-
-
Net income
-21.79M
-24.61M
-92.40M
-23.28M
Net profit margin
-
-
-852.06%
-2,240.90%
Earnings per share
-3.72
-1.37
-4.92
-0.70
Interest and investment income
313.00K
1.28M
1.10M
1.45M
Interest expense
-1.07M
-
-
-
Net interest expenses
-760.00K
1.28M
1.10M
1.45M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.03M
-25.86M
-91.44M
-24.66M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer